Lamivudine/tenofovir disoproxil

Lamivudine/tenofovir disoproxil is a combination medication used in the treatment of HIV/AIDS. It contains two antiretroviral drugs, lamivudine and tenofovir disoproxil, which work together to prevent the HIV virus from replicating in the body.

Composition

The medication is composed of two active ingredients: lamivudine and tenofovir disoproxil. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), while tenofovir disoproxil is a prodrug of tenofovir, an adenosine analogue reverse transcriptase inhibitor (NtRTI).

Mechanism of Action

Both lamivudine and tenofovir disoproxil work by inhibiting the action of reverse transcriptase, an enzyme that the HIV virus needs to replicate itself. By blocking this enzyme, the medication prevents the virus from multiplying, which helps to control the level of virus in the body.

Usage

Lamivudine/tenofovir disoproxil is used in combination with other antiretroviral drugs as part of a regimen for the treatment of HIV/AIDS. It is also used in the treatment of chronic hepatitis B.

Side Effects

Common side effects of lamivudine/tenofovir disoproxil include nausea, diarrhea, and headache. Serious side effects may include liver problems, lactic acidosis, and worsening of hepatitis B in those already infected.

Precautions

Before starting treatment with lamivudine/tenofovir disoproxil, patients should inform their healthcare provider if they have kidney disease, liver disease (including hepatitis B or C), or a history of mental illness or substance abuse.

See Also

• Antiretroviral therapy
• HIV/AIDS
• Hepatitis B

This HIV related article is a stub. You can help WikiMD by expanding it.